Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

134.35 +1.44 (+1.08%)
Streaming Delayed Price Updated: 12:58 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
3 Stocks to Buy for the Next Bull Run: March 2024
Look for these stocks to buy to continue moving higher in coming quarters propelled by multiple catalysts and strong earnings. 
Via InvestorPlace
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy?
Their joint project is cutting-edge, but it won't pay off immediately. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Viking Surges After Weight-Loss Pill Tops Expectations In Just 28 Days
People lost more weight than the company expected over a 28-day study. 
Via Investor's Business Daily
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
All three of these high-flying stocks could have more room to run. 
Via The Motley Fool
Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.
Among its other key ratings Dexcom has a near-best 98 Earnings Per Share Rating out of 99, reflecting strong profit growth this past year. 
Via Investor's Business Daily
Looking At Novo Nordisk's Recent Unusual Options Activity
Via Benzinga
Decoding 7 Analyst Evaluations For Novo Nordisk
Via Benzinga
Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market
Artificial intelligence (AI) could play a big role in medical breakthroughs. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
Raymond James Financial, Inc. (NYSE: RJF) is now valued more highly than JPMorgan Chase & Co. (NYSE: JPM), according to Jim Cramer. 
Via Benzinga
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants. 
Via The Motley Fool
Is Viking Therapeutics Stock a Millionaire Maker?
Viking Therapeutics has become one of the hottest healthcare stocks of 2024. 
Via The Motley Fool
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
How Are Obesity Drugs And Nvidia Related? Success Of Ozempic, Wegovy Propels Novo Nordisk Foundation To Fund Nvidia-Powered AI Supercomputer For Faster Drug Development
Novo Nordisk Foundation partners with Eviden and Nvidia to pioneer AI-driven healthcare solutions. Expect the Gefion supercomputer to revolutionize drug discovery, supported by tech giants and the Novo... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
Legal actions surge against diabetes drug manufacturers Eli Lilly and Novo Nordisk. Patients allege severe complications, including gallbladder issues and gastroparesis, tied to GLP-1 agonists. Over 60... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs. 
Via The Motley Fool
Did Eli Lilly Just One-Up Novo Nordisk?
Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments. 
Via The Motley Fool
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now. 
Via InvestorPlace
Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.
Novo Nordisk's Wegovy recently gained Food and Drug Administration approval to reduce the risk of cardiovascular problems. 
Via Investor's Business Daily
Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health
Medicare considers extending coverage for Novo Nordisk's Wegovy to eligible members with heart disease history. CMS may include anti-obesity drugs under certain Medicare Part D plans. Germany's health... 
Via Benzinga
7 Stocks That Are Creating a Buzz on Wall Street
Buy these stocks creating buzz in order to inject some green into your portfolio and give your investment returns a boost. 
Via InvestorPlace
Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy
Has Novo Nordisk's already red-hot stock become an even better buy? 
Via The Motley Fool
Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions
Eli Lilly stock is up 32% so far in 2024 and has risen 318% over three years. 
Via Benzinga
3 Biopharma Stocks Predicted to Soar in Q2 2024
These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk Stock Stalls On Oprah TV Special, But Reddit Traders Believe It's 'Not Done Yet'
Retail investors are talking about a slim group of topics on Reddit this week including Novo Nordisk, weight-loss drug Ozempic and talk show host Oprah Winfrey. 
Via Benzinga
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
The gap has been shrinking between these stocks over the past month. 
Via The Motley Fool
Tesla Investor Ross Gerber Backs Ozempic's Potential To Reduce Monthly Food Expenses — Less Eating, More Saving
Ross Gerber, a prominent Tesla investor, has suggested that the use of Ozempic could lead to significant cost savings. 
Via Benzinga
3 Juicy Stocks Serving Up 5% Dividends That You Can Snag for $50
These dividend stocks selling for under $50 with yields of 5% or more offer a lot to investors at any time making these strong buys. 
Via InvestorPlace
What Retail Apocalypse? 7 Stocks Proving the Doomsayers Wrong.
People have said retail is dying for years now but the supposed apocalypse is nowhere to be found with these fast-charging retail stocks. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.